Table 2.
Univariate analysis comparing antibiotic regimens in definitive therapy between survivors and non-survivors at 30 days from infection onset
| Antibiotic therapy* | Survivors n = 79 (%) |
Non-survivors n = 101 (%) |
P |
|---|---|---|---|
| Use of only 1 antibiotic | 9 (11.4) | 14 (13.9) | 0.66 |
| Use of 2 antibiotics in combination | 40 (50.6) | 48 (47.5) | 0.764 |
| Use of 3 antibiotics in combination | 25 (31.6) | 30 (29.7) | 0.871 |
| Use of 4 antibiotics in combination | 4 (5.1) | 9 (8.9) | 0.656 |
| Use of 5 antibiotics in combination | 1 (1.3) | 0 | 0.439 |
| Colistin-containing regimen | 67 (84.8) | 84 (83.2) | 0.84 |
| Tigecycline-containing regimen | 14 (17.7) | 28 (27.7) | 0.155 |
| Aminoglycoside-containing regimen | 4 (5.1) | 7 (6.9) | 1.0 |
| Rifampin-containing regimen | 23 (29.1) | 30 (29.7) | 1.0 |
| Ampicillin/sulbactam-containing regimen | 0 | 2 (2) | 0.505 |
| Fosfomycin-containing regimen | 37 (46.8) | 7 (6.9) | < 0.001 |
| Trimethoprim/sulfamethoxazole-containing regimen | 1 (1.3) | 2 (2) | 1.0 |
| Vancomycin-containing regimen | 8 (10.1) | 3 (3) | 0.061 |
| Carbapenem-containing regimen | 44 (55.7) | 61 (60.3) | 0.765 |
| Use of colistin aerosol inhalation therapy | 13 (16.5) | 17 (16.8) | 1.0 |
| Length of definitive antibiotic therapy, mean ± SD (days) | 12.9 ± 9.4 | 9.5 ± 4.4 | 0.014 |
| Time to initial definitive therapy, mean ± SD (days) | 3.8 ± 1.8 | 3.6 ± 1.6 | 0.872 |
SD standard deviation
Bold values indicate statistical significance (p ≤ 0.05)